Mathematical model of endothelial cell proliferation and maturation
Digital Object Identifier (DOI): 10.14708/ma.v46i1.6383
Abstract
Blood vessel sprouting (angiogenesis) is one of the hallmarks of cancer. Better quantitative understanding of this process would allow more effective antiangiogenic therapies to be developed. It has been hypothesised that not only the number of endothelial cells, but also the quality of the vasculature play an important role in how chemo- and radiotherapies are delivered to tumour site. Hence in this study a minimally-parametrised mathematical model of endothelial cell proliferation and maturation is developed. Endothelial cells are subdivided into two compartments -- mature and immature (or proliferating). The cells are assumed to undergo a self-mediated maturation, while loss of blood vessel quality is mediated by an external growth factor (here VEGF). The model is fitted to experimental data. The model shows how inhibition of VEGF results in better quality vasculature and slower proliferation.
Keywords: Angiogenesis, mathematical modelling, tumour growth, vascular endothelial growth factor
Subject classification: 92C50; 37N25; 92B05
References
[1] T. Alarcón, H. M. Byrne, and P. K. Maini. Multiscale modelling of tumour growth and therapy: the influence of vessel normalisation on chemotherapys. Computational and Mathematical Methods in Medicine, 7:85-119, 2006. doi: 10.1080/10273660600968994.
[2] J. Folkman. Tumor angiogenesis. therapeutic implications. New England Journal of Medicine, 285:1182-1186, 1971. doi:10.1056/NEJM197111182852108.
[3] P. Hahnfeldt, D. Panigrahy, J. Folkman, and L. Hlatky. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Research, 59: 4770-4775, 1999.
[4] R. Jain. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science, 307:58-62, 2005. doi: 10.1126/science. 1104819.
[5] J. Poleszczuk and I. Skrzypczak. Tumour angiogenesis model with variable vessels' effectiveness. Applicationes Mathematica, 38:33-49, 2011. doi: 10.14708/ma.v41i1.382.
[6] D. Ribatti. Judah Folkman, a pioneer in the study of angiogenesis. Angiogenesis, 11:3-10, 2008. doi: 10.1007/s10456-008-9092-6.
[7] A. Wolfe, B. O'Clair, V. E. Groppi, and D. P. McEwen. Pharmacologic
characterization of a kinetic in vitro human co-culture angiogenesis model using clinically relevant compounds. Journal of Biomolecular Screening, 18:1234-1245, 2013. doi: 10.1177/1087057113502085.
[2] J. Folkman. Tumor angiogenesis. therapeutic implications. New England Journal of Medicine, 285:1182-1186, 1971. doi:10.1056/NEJM197111182852108.
[3] P. Hahnfeldt, D. Panigrahy, J. Folkman, and L. Hlatky. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Research, 59: 4770-4775, 1999.
[4] R. Jain. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science, 307:58-62, 2005. doi: 10.1126/science. 1104819.
[5] J. Poleszczuk and I. Skrzypczak. Tumour angiogenesis model with variable vessels' effectiveness. Applicationes Mathematica, 38:33-49, 2011. doi: 10.14708/ma.v41i1.382.
[6] D. Ribatti. Judah Folkman, a pioneer in the study of angiogenesis. Angiogenesis, 11:3-10, 2008. doi: 10.1007/s10456-008-9092-6.
[7] A. Wolfe, B. O'Clair, V. E. Groppi, and D. P. McEwen. Pharmacologic
characterization of a kinetic in vitro human co-culture angiogenesis model using clinically relevant compounds. Journal of Biomolecular Screening, 18:1234-1245, 2013. doi: 10.1177/1087057113502085.
Pages: 3-12
Full Text: PDF


